-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Wednesday's After-Market Session

Benzinga·03/19/2025 21:06:24
Listen to the news

Gainers

  • Brainstorm Cell (NASDAQ:BCLI) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million.
  • Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million.
  • Shuttle Pharmaceuticals (NASDAQ:SHPH) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million.
  • Century Therapeutics (NASDAQ:IPSC) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million.
  • Longevity Health Holdings (NASDAQ:XAGE) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million.
  • FibroGen (NASDAQ:FGEN) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago.

Losers

  • Akebia Therapeutics (NASDAQ:AKBA) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago.
  • Dyadic International (NASDAQ:DYAI) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million.
  • cbdMD (AMEX:YCBD) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million.
  • Scienture Holdings (NASDAQ:SCNX) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million.
  • Venus Concept (NASDAQ:VERO) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million.
  • LENZ Therapeutics (NASDAQ:LENZ) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.